The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Keryx Biopharmaceuticals Inc

Nasdaq: KERX
Last

(U.S.) $5.85

Today's change-0.33 -5.34%
Updated September 1 4:00 PM -4GMT. Delayed by at least 15 minutes.
 

Keryx Biopharmaceuticals Inc

Nasdaq: KERX
Last

(U.S.) $5.85

Today's change-0.33 -5.34%
Updated September 1 4:00 PM -4GMT. Delayed by at least 15 minutes.

Keryx Biopharmaceuticals Inc down (U.S.)$0.33

Keryx Biopharmaceuticals Inc closed sharply lower Tuesday, dropping (U.S.)$0.33 or 5.34% to (U.S.)$5.85. Over the last five days, shares have gained 4.28%, but are down 58.66% for the last year to date. Shares have underperformed the S&P 500 by 63.37% during the last year.

Key company metrics

  • Open(U.S.) $6.03
  • Previous close(U.S.) $6.18
  • High(U.S.) $6.24
  • Low(U.S.) $5.80
  • Bid / Ask(U.S.) $5.79 / (U.S.) $6.41
  • YTD % change-58.66%
  • Volume863,467
  • Average volume (10-day)1,343,342
  • Average volume (1-month)1,699,508
  • Average volume (3-month)1,598,418
  • 52-week range(U.S.) $5.25 to (U.S.) $18.42
  • Beta3.48
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.35
Updated September 1 4:00 PM -4GMT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-2,884.14%

Keryx Biopharmaceuticals Inc has a net profit margin of -2,884.14%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX2.72%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q1/2015Q4/2014Q3/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014
Revenue3110
Total other revenue--------
Total revenue3110
Gross profit2100
Total cost of revenue1100
Total operating expense29294036
Selling / general / administrative21193416
Research & development810619
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-27-28-40-35
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-27-28-40-35
Income after tax-27-28-40-35
Income tax, total0010
Net income-27-28-40-35
Total adjustments to net income--------
Net income before extra. items-27-28-40-35
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-27-28-40-35
Inc. avail. to common incl. extra. items-27-28-40-35
Diluted net income-27-28-40-35
Dilution adjustment--------
Diluted weighted average shares1051019292
Diluted EPS excluding extraordinary itemsvalue per share-0.26-0.28-0.44-0.38
Dividends per sharevalue per share0.000.00--0.00
Diluted normalized EPSvalue per share-0.26-0.28-0.44-0.38